ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
i2O Therapeutics has launched with $4 million in seed funding from Sanofi Ventures and the JDRF T1D Fund to develop ionic liquid–based drug delivery technology. Using ionic liquid technology from the lab of Harvard University bioengineer Samir Mitragotri, i2O hopes to create oral forms of drugs that now must be delivered via needle. Its first target is GLP-1analogs, which help balance glucose levels to treat diabetes.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X